A 68-year-old man with Parkinson's disease presents to the neurology clinic with complaints of tremor and rigidity that have worsened over the past 3 months despite optimized levodopa therapy. His wife reports that he has also developed urinary hesitancy and constipation. On examination, he has a resting tremor, cogwheel rigidity, and bradykinesia. His post-void residual urine volume is 120 mL. The neurologist decides to add an anticholinergic agent to improve motor symptoms. Which of the following anticholinergic drugs is most appropriate for this patient, considering his age and the need to avoid cognitive side effects?

Explanation

## Anticholinergic Drugs in Parkinson's Disease ### Clinical Context In elderly patients with Parkinson's disease, anticholinergic agents are used as adjunctive therapy to reduce tremor and rigidity when levodopa therapy is insufficient. However, drug selection must carefully account for age-related pharmacokinetics and the risk of cognitive impairment, as elderly patients are particularly vulnerable to central anticholinergic toxicity. ### Why Benztropine Is Most Appropriate **Key Point:** Benztropine (a tertiary amine like the other options) is preferred in elderly Parkinson's patients due to its **shorter duration of action, lower anticholinergic burden at therapeutic doses, and better overall tolerability profile** compared to trihexyphenidyl, scopolamine, and atropine. **High-Yield:** Benztropine has: - Shorter duration of action (4–6 hours) allowing flexible, lower-dose dosing - Lower incidence of central anticholinergic side effects (confusion, hallucinations, delirium) at therapeutic doses compared to trihexyphenidyl - Dual anticholinergic and antihistamine properties that contribute to its antiparkinsonian effect - Established use in elderly PD patients as per KD Tripathi and Harrison's guidelines ### Comparison of Anticholinergic Agents | Drug | Primary Use in PD | Cognitive Risk in Elderly | Notes | |------|-------------------|--------------------------|-------| | Benztropine | Yes (preferred in elderly) | Lower (at therapeutic doses) | Shorter duration, better tolerated | | Trihexyphenidyl | Yes (but avoid in elderly) | Higher | Longer duration, more CNS side effects | | Scopolamine | No (not used for PD motor sx) | High | Used for motion sickness/nausea | | Atropine | No (not used for PD motor sx) | High | Systemic use; not indicated for PD | **Clinical Pearl:** All anticholinergic drugs used in Parkinson's disease (benztropine, trihexyphenidyl) are **tertiary amines** and do cross the blood–brain barrier. The advantage of benztropine over trihexyphenidyl in elderly patients lies in its **shorter duration of action and lower propensity for cognitive side effects at equivalent therapeutic doses**, not in selective M1 receptor antagonism or reduced BBB penetration (KD Tripathi, Essentials of Medical Pharmacology, 8th ed.; Harrison's Principles of Internal Medicine, 21st ed.). ### Mechanism in Parkinson's Disease Anticholinergic drugs block muscarinic receptors in the basal ganglia, reducing the relative excess of cholinergic activity that occurs when dopamine is deficient. This helps restore the dopamine–acetylcholine balance and reduces tremor and rigidity. **Warning:** This patient already has urinary hesitancy and constipation — peripheral anticholinergic effects. Benztropine is chosen here as the least cognitively harmful option among those listed, but close monitoring for worsening urinary retention and bowel symptoms is essential. Trihexyphenidyl, scopolamine, and atropine carry a higher risk of delirium and cognitive decline in elderly patients and should be avoided.